Literature DB >> 3321878

A double-masked crossover study comparing the effects of carteolol 1% and 2% on intra-ocular pressure.

G R Duff1.   

Abstract

No significant difference was found between carteolol 1% and 2%, when their effects on intraocular pressure were compared over a 4 week treatment period. Twenty ocular hypertensive subjects were recruited for this double-masked crossover trial.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3321878     DOI： 10.1111/j.1755-3768.1987.tb07052.x

Source DB:  PubMed          Journal:  Acta Ophthalmol (Copenh)        ISSN： 0001-639X


  3 in total

Review 1.  Ocular carteolol. A review of its pharmacological properties, and therapeutic use in glaucoma and ocular hypertension.

Authors:  P Chrisp; E M Sorkin
Journal:  Drugs Aging       Date:  1992 Jan-Feb       Impact factor: 3.923

2.  Safety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy.

Authors:  Norbert Pfeiffer; Maria-Luise Scherzer; Hubert Maier; Sonja Schoelzel; Mark C Jasek; Jeanette A Stewart; William C Stewart
Journal:  Clin Ophthalmol       Date:  2010-05-14

3.  Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension.

Authors:  E D Sharpe; D G Day; C J Beischel; J S Rhodes; J A Stewart; W C Stewart
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.